Cabaletta Bio, Inc. (CABA) Stock Forecast
CABA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 10 analysts
- Price target
- $13.25 average of analyst targets
- Upside to target
- +839.7% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.33
- 52-week range
- $1.41 – $4.15
CABA analyst ratings
10 analystsNumber of analysts at each rating.
CABA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CABA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.34 | −$0.24 | −$0.44 | +30.5% | 5 |
| Current fiscal year (2026) | −$1.36 | −$1.55 | −$1.15 | −$2.10 | +35.4% | 5 |
| Next fiscal year (2027) | −$1.19 | −$1.29 | −$1.02 | −$1.36 | +12.3% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CABA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 7 |
CABA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CABA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.31 | −$0.31 | −$0.31 | −$0.31 | −$0.31 | −2.8% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.34 | −$1.34 | −$1.36 | −$1.36 | −$1.36 | +1.3% | 1 up · 2 down |
| Next fiscal year (2027) | −$1.42 | −$1.42 | −$1.48 | −$1.48 | −$1.19 | −16.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CABA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CABA beat in 6 of 12.
What analysts expect from CABA
10 analysts cover Cabaletta Bio; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.25, 839.7% above the latest close of $1.41. Analysts expect earnings of −$1.36 per share for 2026, +35.4% from a year earlier. For 2027 the average estimate is −$1.19 per share. Cabaletta Bio beat the EPS estimate in 6 of the last 12 quarters.
Related: CABA income statement, CABA key metrics, CABA chart. See the CABA stock overview for the latest quote and news.
CABA forecast FAQ
What is Cabaletta Bio's price target?
The average analyst price target for Cabaletta Bio is $13.25, 839.7% above the latest close of $1.41.
Is Cabaletta Bio a buy, hold or sell?
Of 10 analysts covering Cabaletta Bio, 7 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cabaletta Bio's EPS forecast?
Analysts forecast −$1.36 per share for 2026 (range −$1.55 to −$1.15); for 2027 the estimate is −$1.19.
When does Cabaletta Bio report earnings?
Cabaletta Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.33.
Does Cabaletta Bio usually beat earnings estimates?
Cabaletta Bio reported EPS at or above the analyst estimate in 6 of the last 12 quarters.